Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.

L. Mantovani, S. Ménard, D. Mezzanzanica, S. Miotti, S. M. Pupa, M. I. Colnaghi

Research output: Contribution to journalArticle

Abstract

Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. A high variability of the immunoreactive values was observed by analysing different preparations of radiolabelled MOv18 (from 12 to 21% on OvCa432 and from 22 to 56% on IGROV1) and by using the same radiolabelled preparation (12% on OvCa432 and 51% on IGROV1). Since the variability could be due to the target cells, we set up an alternative binding assay using the anti-idiotypic MAb anti-Id18.1 directed against a private idiotype closely associated with the MOv18 paratope. Three different experiments carried out with the anti-idiotypic MAb gave reproducible results with an immunoreactive range from 71 to 83%. A direct comparison between the reactivity of the same 125I-MOv18 preparation on anti-Id18.1 and on IGROV1 confirmed the higher value of the immunoreactive fraction estimated on the more homogeneous anti-idiotypic reagent (71%), rather than on the tumour cells (56%). These data suggest that anti-idiotypic MAbs could represent suitable reagents for the evaluation of the immunoreactivity of an antibody preparation after radiolabelling and before in vivo administration.

Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalThe British journal of cancer. Supplement
Volume10
Publication statusPublished - Jul 1990

Fingerprint

Neoplasm Antibodies
Monoclonal Antibodies
Antibody Binding Sites
Carcinoma
Ovary
Cell Line
Antibodies
Neoplasms
MOv18 monoclonal antibody

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. / Mantovani, L.; Ménard, S.; Mezzanzanica, D.; Miotti, S.; Pupa, S. M.; Colnaghi, M. I.

In: The British journal of cancer. Supplement, Vol. 10, 07.1990, p. 15-17.

Research output: Contribution to journalArticle

@article{9693b8470cd24a8f99dbc40f754a62aa,
title = "Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.",
abstract = "Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. A high variability of the immunoreactive values was observed by analysing different preparations of radiolabelled MOv18 (from 12 to 21{\%} on OvCa432 and from 22 to 56{\%} on IGROV1) and by using the same radiolabelled preparation (12{\%} on OvCa432 and 51{\%} on IGROV1). Since the variability could be due to the target cells, we set up an alternative binding assay using the anti-idiotypic MAb anti-Id18.1 directed against a private idiotype closely associated with the MOv18 paratope. Three different experiments carried out with the anti-idiotypic MAb gave reproducible results with an immunoreactive range from 71 to 83{\%}. A direct comparison between the reactivity of the same 125I-MOv18 preparation on anti-Id18.1 and on IGROV1 confirmed the higher value of the immunoreactive fraction estimated on the more homogeneous anti-idiotypic reagent (71{\%}), rather than on the tumour cells (56{\%}). These data suggest that anti-idiotypic MAbs could represent suitable reagents for the evaluation of the immunoreactivity of an antibody preparation after radiolabelling and before in vivo administration.",
author = "L. Mantovani and S. M{\'e}nard and D. Mezzanzanica and S. Miotti and Pupa, {S. M.} and Colnaghi, {M. I.}",
year = "1990",
month = "7",
language = "English",
volume = "10",
pages = "15--17",
journal = "The British journal of cancer. Supplement",
issn = "0306-9443",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.

AU - Mantovani, L.

AU - Ménard, S.

AU - Mezzanzanica, D.

AU - Miotti, S.

AU - Pupa, S. M.

AU - Colnaghi, M. I.

PY - 1990/7

Y1 - 1990/7

N2 - Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. A high variability of the immunoreactive values was observed by analysing different preparations of radiolabelled MOv18 (from 12 to 21% on OvCa432 and from 22 to 56% on IGROV1) and by using the same radiolabelled preparation (12% on OvCa432 and 51% on IGROV1). Since the variability could be due to the target cells, we set up an alternative binding assay using the anti-idiotypic MAb anti-Id18.1 directed against a private idiotype closely associated with the MOv18 paratope. Three different experiments carried out with the anti-idiotypic MAb gave reproducible results with an immunoreactive range from 71 to 83%. A direct comparison between the reactivity of the same 125I-MOv18 preparation on anti-Id18.1 and on IGROV1 confirmed the higher value of the immunoreactive fraction estimated on the more homogeneous anti-idiotypic reagent (71%), rather than on the tumour cells (56%). These data suggest that anti-idiotypic MAbs could represent suitable reagents for the evaluation of the immunoreactivity of an antibody preparation after radiolabelling and before in vivo administration.

AB - Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. A high variability of the immunoreactive values was observed by analysing different preparations of radiolabelled MOv18 (from 12 to 21% on OvCa432 and from 22 to 56% on IGROV1) and by using the same radiolabelled preparation (12% on OvCa432 and 51% on IGROV1). Since the variability could be due to the target cells, we set up an alternative binding assay using the anti-idiotypic MAb anti-Id18.1 directed against a private idiotype closely associated with the MOv18 paratope. Three different experiments carried out with the anti-idiotypic MAb gave reproducible results with an immunoreactive range from 71 to 83%. A direct comparison between the reactivity of the same 125I-MOv18 preparation on anti-Id18.1 and on IGROV1 confirmed the higher value of the immunoreactive fraction estimated on the more homogeneous anti-idiotypic reagent (71%), rather than on the tumour cells (56%). These data suggest that anti-idiotypic MAbs could represent suitable reagents for the evaluation of the immunoreactivity of an antibody preparation after radiolabelling and before in vivo administration.

UR - http://www.scopus.com/inward/record.url?scp=0025456446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025456446&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 15

EP - 17

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

SN - 0306-9443

ER -